

Nr. crt.	Cod protocol	Numar EudraCT	Medicament de investigatie clinica testat	Medicament de investigatie clinica comparator	Placebo	Aria terapeutică	Sponsor	International / national	Denumirea studiului (s-a pastrat denumirea originala - in limba engleza)	Faza	Nr. estimat de pacienti pentru Romania	Data autorizarii studiului clinic de catre ANMDM	Data opiniei CNBMDM	Data inceperii studiului	Inchidere studiu la nivel global/ Romania	Inchidere temporara
1	MK-5592-069	2011-003938-14	Posaconazole	Vfend® (voriconazole)	Da	Infecții bacteriene și micoze	Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., SUA	multicentric	A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults and Adolescents (Phase 3; Protocol No. MK-5592-069)	III	6	1/11/2019	11/20/2017			
2	54767414AMY3001	2016-001737-27	Daratumumab in combinatie cu Cyclophosphamide, Bortezomib si Dexamethasone (CyBorD)	CyBorD	Nu	Afecțiuni oncologice	Janssen-Cilag International N.V., Belgia	unicentric	A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis	III	8	1/23/2019	5/21/2018	3/6/2019		
3	D0816C00020	2017-002767-17	Olaparib AZD2281	Nu	Nu	Afecțiuni oncologice	AstraZeneca AB, Suedia	multicentric	A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed non-Germline BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy	III	30	1/17/2019	11/1/2018			
4	TransCon_hGH_CT-301EXT,	2017-003410-20	TransCon hGH (ACP-011)	Nu	Nu	Afecțiuni hormonale	Ascendis Pharma Endocrinology Division A/S, Danemarca	unicentric	A Multicenter, Phase 3, Long-term, Open-label Trial Investigating Safety and Efficacy of TransCon hGH Administered Once-Weekly in Children with Growth Hormone Deficiency (GHD) Who Have Completed a Prior TransCon hGH Clinical Trial	III	3	1/17/2019		1/28/2019		
5	CA209-592	2018-000462-11	Nivolumab in combinatie cu Ipilimumab	Nu	Nu	Afecțiuni oncologice	Bristol-Myers Squibb International Corporation, Belgia	multicentric	An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC)	II	12	1/18/2019				
6	CYC-202	2018-003349-41	ST-0529	Nu	Da	Afecțiuni ale sistemului digestiv	Sublimity Therapeutics (Hold Co) Ltd., Irlanda	multicentric	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of ST-0529 in Subjects with Moderately to Severely Active Ulcerative Colitis	II	40	1/11/2019		14.03.2019		
7	205801	2018-001316-29	Novel Regimens	Standard of Care	Nu	Afecțiuni oncologice	GlaxoSmithKline Research and Development Ltd., UK	multicentric	A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants	II	12	1/18/2019				